This is a case series of 10 patients who had staphylococcal biofilm infections that were treated with adjuvant rifabutin therapy instead of rifampin therapy. In these cases, rifampin was contraindicated secondary to drug&ndash / drug interactions with the patients&rsquo / chronic medications. Rifabutin therapy was well tolerated with no side effect...
Bolniki z rakom se pogosto poslužujejo pripravkov za samozdravljenje, od zdravil brez recepta do prehranskih dopolnil in drugih pripravkov, kljub pomanjkanju dokazov o njihovi varnosti, kakovosti in učinkovitosti. Namen raziskave je bil opredeliti pripravke za samozdravljenje, ki jih uporabljajo bolniki v gastroonkološki ambulanti Kliničnega oddelk...
Published in Therapeutic Drug Monitoring
COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppresse...
Published in Forum of Clinical Oncology
The emergence of cyclin-dependent kinase (CDK) 4 and 6 inhibitors has brought a new approach in the treatment of advanced hormone receptor (HR) positive breast cancer and human epidermal growth factor (HER) 2 negative breast cancer. To date, three CDK 4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, are approved by the Food and Drug Admini...
Published in British Journal of Clinical Pharmacology
Published in Journal of Basic and Clinical Physiology and Pharmacology
Background Osteoarthritis (OA) is a chronic degenerative joint disease, characterized by physiological disorders, such as cartilage degradation, bone remodeling, osteophyte formation, and joint inflammation, which results in pain. Several studies have reported problems with the use of pain medications in OA, such as the use of a combination of many...
Published in Australian Prescriber
Drug interactions can lead to significant toxicity or loss of clinical effect. The risks increase with the number of drugs the patient takes General and specialised drug interaction resources are available. Access to up-to-date electronic resources is encouraged There are gaps in the information on interactions for new drugs, those with complicated...
Published in British journal of clinical pharmacology
The pharmacy reference database, Micromedex, lists concomitant hydrochlorothiazide and cyclophosphamide use as a potential, major drug-drug interaction (DDI), although only one small, single-center study supports this claim. Our objective was to estimate associations between this potential DDI and two adverse chemotherapy-related events, neutropeni...
Published in Frontiers in Pharmacology
Long-term use of imatinib is effective and well-tolerated in children with chronic myeloid leukaemia (CML) yet defining an optimal dosing regimen for imatinib in younger patients is a challenge. The potential interactions between imatinib and coadministered drugs in this “special” population also remains largely unexplored. This study implements a ...
